Toshihiko Fujii

3.5k total citations
89 papers, 2.2k citations indexed

About

Toshihiko Fujii is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Toshihiko Fujii has authored 89 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Molecular Biology, 17 papers in Oncology and 16 papers in Organic Chemistry. Recurrent topics in Toshihiko Fujii's work include Pharmacogenetics and Drug Metabolism (15 papers), Drug Transport and Resistance Mechanisms (13 papers) and Nuclear physics research studies (9 papers). Toshihiko Fujii is often cited by papers focused on Pharmacogenetics and Drug Metabolism (15 papers), Drug Transport and Resistance Mechanisms (13 papers) and Nuclear physics research studies (9 papers). Toshihiko Fujii collaborates with scholars based in Japan, United States and Switzerland. Toshihiko Fujii's co-authors include Hisashi Miyazaki, Kiyoaki Sakata, Yoshiaki Terauchi, Yuko Aoki, Hirosato Ebiike, Takanori Hashizume, Tetsuya Kamataki, Nobuo Shimma, Masashi Mise and Nobuya Ishii and has published in prestigious journals such as Journal of the American Chemical Society, Physical Review Letters and PLoS ONE.

In The Last Decade

Toshihiko Fujii

88 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Toshihiko Fujii Japan 28 751 458 380 359 275 89 2.2k
Patrick Young United States 29 691 0.9× 468 1.0× 198 0.5× 73 0.2× 250 0.9× 114 2.4k
Robert T. Gampe United States 22 2.0k 2.7× 256 0.6× 282 0.7× 61 0.2× 100 0.4× 49 2.9k
Kanji Meguro Japan 20 857 1.1× 764 1.7× 221 0.6× 44 0.1× 91 0.3× 63 2.2k
Robert X. Xu United States 22 1.5k 2.0× 251 0.5× 339 0.9× 132 0.4× 28 0.1× 30 2.3k
Hans Senn Switzerland 31 3.9k 5.1× 139 0.3× 460 1.2× 97 0.3× 253 0.9× 54 5.5k
David P. Cistola United States 35 2.6k 3.4× 378 0.8× 874 2.3× 60 0.2× 95 0.3× 76 3.9k
Hiroyuki Kimura Japan 27 1.1k 1.4× 364 0.8× 415 1.1× 25 0.1× 188 0.7× 163 3.1k
Gildas Bertho France 23 1.0k 1.4× 386 0.8× 128 0.3× 140 0.4× 24 0.1× 87 1.9k
Daniel S. Sem United States 24 1.1k 1.4× 170 0.4× 184 0.5× 186 0.5× 30 0.1× 86 1.8k
G. Raciti Italy 27 583 0.8× 106 0.2× 135 0.4× 49 0.1× 264 1.0× 99 2.0k

Countries citing papers authored by Toshihiko Fujii

Since Specialization
Citations

This map shows the geographic impact of Toshihiko Fujii's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Toshihiko Fujii with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Toshihiko Fujii more than expected).

Fields of papers citing papers by Toshihiko Fujii

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Toshihiko Fujii. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Toshihiko Fujii. The network helps show where Toshihiko Fujii may publish in the future.

Co-authorship network of co-authors of Toshihiko Fujii

This figure shows the co-authorship network connecting the top 25 collaborators of Toshihiko Fujii. A scholar is included among the top collaborators of Toshihiko Fujii based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Toshihiko Fujii. Toshihiko Fujii is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Komatsu, Shunichiro, Yoko Kayukawa, Yoko Miyazaki, et al.. (2022). Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial. Scientific Reports. 12(1). 12312–12312. 10 indexed citations
2.
Sase, Hitoshi, Yoshito Nakanishi, Satoshi Aida, et al.. (2018). Acquired JHDM1D–BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2 -Amplified Gastric Cancer. Molecular Cancer Therapeutics. 17(10). 2217–2225. 17 indexed citations
3.
Tanaka, Hiroshi, Hitoshi Sase, Toshiyuki Tsukaguchi, et al.. (2018). Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer. Molecular Cancer Therapeutics. 17(12). 2519–2529. 17 indexed citations
4.
Nakanishi, Yoshito, Toshiyuki Tsukaguchi, Toshihiko Fujii, et al.. (2015). Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3–BAIAP2L1. Molecular Cancer Therapeutics. 14(3). 704–712. 51 indexed citations
5.
Nakanishi, Yoshito, Hideaki Mizuno, Hitoshi Sase, et al.. (2015). ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor. Molecular Cancer Therapeutics. 14(12). 2831–2839. 24 indexed citations
6.
Sano, Yuji, Eri Hashimoto, Noriaki Nakatani, et al.. (2014). Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression. Molecular Cancer Therapeutics. 14(2). 533–541. 22 indexed citations
7.
Nakanishi, Yoshito, Toshiyuki Tsukaguchi, Toshihiko Fujii, et al.. (2014). The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor. Molecular Cancer Therapeutics. 13(11). 2547–2558. 101 indexed citations
8.
Ono, Naomi, Toshikazu Yamazaki, Yoshito Nakanishi, et al.. (2011). Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)‐overexpressing cancers. Cancer Science. 103(2). 342–349. 21 indexed citations
9.
Tanaka, Hiroshi, Miyuki Yoshida, Hiromi Tanimura, et al.. (2011). The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations. Clinical Cancer Research. 17(10). 3272–3281. 79 indexed citations
10.
Matsumoto, Satoshi, et al.. (2011). Disposition of Exogenous Urea and Effects of Diet in Rats. Arzneimittelforschung. 56(3). 258–266. 2 indexed citations
11.
Yabuki, Nami, Kiyoaki Sakata, Tomoaki Yamasaki, et al.. (2007). Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance. Cancer Genetics and Cytogenetics. 173(1). 1–9. 58 indexed citations
12.
Hashizume, Takanori, Susumu Imaoka, Masashi Mise, et al.. (2002). Involvement of CYP2J2 and CYP4F12 in the Metabolism of Ebastine in Human Intestinal Microsomes. Journal of Pharmacology and Experimental Therapeutics. 300(1). 298–304. 136 indexed citations
13.
Yamazaki, Hiroshi, et al.. (2002). A Major Genotype in UDP-glucuronosyltransferase 2B15. Drug Metabolism and Pharmacokinetics. 17(2). 164–166. 3 indexed citations
14.
Tagawa, Masaaki, Michiko Kano, Nobuyuki Okamura, et al.. (2002). Differential cognitive effects of ebastine and (+)‐chlorpheniramine in healthy subjects: Correlation between cognitive impairment and plasma drug concentration. British Journal of Clinical Pharmacology. 53(3). 296–304. 31 indexed citations
15.
Tobe, Yoshito, Toshihiko Fujii, Hideki Matsumoto, et al.. (1996). A New Entry into Cyclo[n]carbons:  [2 + 2] Cycloreversion of Propellane-Annelated Dehydroannulenes. Journal of the American Chemical Society. 118(11). 2758–2759. 44 indexed citations
16.
Sugimoto, Y., Toshihiko Fujii, Y. Fujii, et al.. (1988). Search for structures in the p¯p→π+π−and p¯p→K+K−cross sections between 360 and 760 MeV/c. Physical review. D. Particles, fields, gravitation, and cosmology/Physical review. D. Particles and fields. 37(3). 583–586. 6 indexed citations
17.
Fujii, Toshihiko, et al.. (1984). Disposition and metabolism of [14c]at-2266 I. single administration. Chemotherapy. 32. 117–135. 4 indexed citations
18.
Fujii, Toshihiko, et al.. (1984). . RADIOISOTOPES. 33(8). 519–525. 8 indexed citations
19.
Arai, I., Toshihiko Fujii, H. Ikeda, et al.. (1979). A proton spectrometer/polarimeter for photoreactions below 1 GeV. Nuclear Instruments and Methods. 166(2). 171–186. 4 indexed citations
20.
Kamae, T., I. Arai, Toshihiko Fujii, et al.. (1977). Observation of an Anomalous Structure in Proton Polarization from Deuteron Photodisintegration. Physical Review Letters. 38(9). 468–471. 77 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Patrick Young Breakdown of academic impact, for papers by Robert T. Gampe Breakdown of academic impact, for papers by Kanji Meguro Breakdown of academic impact, for papers by Robert X. Xu Breakdown of academic impact, for papers by Hans Senn Breakdown of academic impact, for papers by David P. Cistola Breakdown of academic impact, for papers by Hiroyuki Kimura Breakdown of academic impact, for papers by Gildas Bertho Breakdown of academic impact, for papers by Daniel S. Sem Breakdown of academic impact, for papers by G. Raciti
Rankless by CCL
2026